-
1دورية أكاديمية
المؤلفون: O. N. Titova, N. A. Kuzubova, A. G. Kozyrev, О. Н. Титова, Н. А. Кузубова, А. Г. Козырев
المساهمون: The article was prepared with the support of PSK Pharma LLC (Russia) in accordance with the current legislation of the Russian Federation and the principles of Good Clinical Practice in scientific publications, Статья подготовлена при поддержке компании ООО «ПСК Фарма» (Россия) в соответствии с действующим законодательством Российской Федерации и принципами Добросовестной практики научных публикаций
المصدر: PULMONOLOGIYA; Том 33, № 6 (2023); 810-818 ; Пульмонология; Том 33, № 6 (2023); 810-818 ; 2541-9617 ; 0869-0189
مصطلحات موضوعية: Респиум®, long-acting muscarinic antagonist, tiotropium bromide, Respium®, длительно действующий антихолинергический препарат, тиотропия бромид
وصف الملف: application/pdf
العلاقة: https://journal.pulmonology.ru/pulm/article/view/4394/3585Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4394/2316Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4394/2318Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4394/2319Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4394/2320Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4394/2321Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4394/2322Test; Всемирная организация здравоохранения. Информационные бюллетени. Хроническая обструктивная болезнь легких (ХОБЛ). Доступно на: https://www.who.int/ru/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-diseaseTest-(copd); Adeloye D., Song P., Zhu Y. et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir. Med. 2022; 10 (5): 447–458. DOI:10.1016/S2213-2600(21)00511-7.; GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet. 2021; 397 (10292): 2337–2360. DOI:10.1016/S0140-6736(21)01169-7.; Lange P., Marott J.L., Vestbo J. et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am. J. Respir. Crit. Care Med. 2012; 186 (10): 975–981. DOI:10.1164/rccm.201207-1299OC.; Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Prevention, Diagnosis and Management of COPD: 2023 Report. Available at: https://goldcopd.org/2023-gold-report-2Test/; Авдеев С.Н., Лещенко И.В., Айсанов З.Р. Новая концепция и алгоритм ведения пациентов с хронической обструктивной болезнью легких. Пульмонология. 2023; 33 (5): 587–594. DOI:10.18093/0869-0189-2023-33-5-587-594.; Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 364 (12): 1093–1103. DOI:10.1056/NEJMoa1008378.; Decramer M.L., Chapman K.R., Dahl R. et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir. Med. 2013; 1 (7): 524–533. DOI:10.1016/S2213-2600(13)70158-9.; Panning C.A., DeBisschop M. Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy. 2003; 23 (2): 183–189. DOI:10.1592/phco.23.2.183.32082.; van Noord J.A., Bantje T.A., Eland M.E. et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax. 2000; 55 (4): 289–294. DOI:10.1136/thorax.55.4.289.; Littner M.R., Ilowite J.S., Tashkin D.P. et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161 (4, Pt 1): 1136–1142. DOI:10.1164/ajrccm.161.4.9903044.; Niewoehner D.E., Lapidus R., Cote C. et al. Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2009; 22 (6): 587–592. DOI:10.1016/j.pupt.2009.08.006.; Cooper C.B. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am. J. Med. 2006; 119 (10, Suppl. 1): 21–31. DOI:10.1016/j.amjmed.2006.08.004.; O'Donnell D.E., Flüge T., Gerken F. et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 2004; 23 (6): 832–840. DOI:10.1183/09031936.04.00116004.; Verkindre C., Bart F., Aguilaniu B. et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration. 2006; 73 (4): 420–427. DOI:10.1159/000089655.; Fležar M., Jahnz-Różyk K., Enache G. et al. SOSPES: SPIRIVA® observational study measuring SGRQ score in routine medical practice in Central and Eastern Europe. Int. J. Chron. Obstruct. Pulmon. Dis. 2013; 8: 483–492. DOI:10.2147/COPD.S45640.; Jahnz-Różyk K., Szepiel P. Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD – real-life experience from an observational study. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10: 613–623. DOI:10.2147/COPD.S77144.; Wallace A.E., Kaila S., Bayer V. et al. Health care resource utilization and exacerbation rates in patients with COPD stratified by disease severity in a commercially insured population. J. Manag. Care Spec. Pharm. 2019; 25 (2): 205–217. DOI:10.18553/jmcp.2019.25.2.205.; Niewoehner D.E., Rice K., Cote C. et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann. Intern. Med. 2005; 143 (5): 317–326. DOI:10.7326/0003-4819-143-5-200509060-00007.; Barr R.G., Bourbeau J., Camargo C.A., Ram F.S.F. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2006; 61 (10): 854–862. DOI:10.1136/thx.2006.063271.; Dusser D., Bravo M.L., Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J. 2006; 27 (3): 547–555. DOI:10.1183/09031936.06.00062705.; Halpin D.M., Vogelmeier C., Pieper M.P. et al. Effect of tiotropium on COPD exacerbations: a systematic review. Respir. Med. 2016; 114: 1–8. DOI:10.1016/j.rmed.2016.02.012.; Calzetta L., Coppola A., Ritondo B.L. et al. The impact of muscarinic receptor antagonists on airway inflammation: a systematic review. Int. J. Chron. Obstruct. Pulmon. Dis. 2021; 16: 257–279. DOI:10.2147/COPD.S285867.; Wedzicha J.A., Calverley P.M., Seemungal T.A. et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177 (1): 19–26. DOI:10.1164/rccm.200707-973OC.; Cheyne L., Irvin-Sellers M.J., White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2015; 2015 (9): CD009552. DOI:10.1002/14651858.CD009552.pub3.; Griffin J., Lee S., Caiado M. et al. Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study. Prim. Care Respir. J. 2008; 17 (2): 104–110. DOI:10.3132/pcrj.2008.00024.; Chapman K.R., Beeh K.M., Beier J. et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm. Med. 2014; 14: 4. DOI:10.1186/1471-2466-14-4.; Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir. Med. 2013; 1 (3): 199–209. DOI:10.1016/S2213-2600(13)70052-3.; Beier J., Kirsten A.M., Mróz R. et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb study. COPD. 2013; 10 (4): 511–522. DOI:10.3109/15412555.2013.814626.; Титова О.Н., Кузубова Н.А., Козырев А.Г., Шумилов А.А. Бронхолитическая терапия при хронической обструктивной болезни легких: что следует учитывать в клинической практике при выборе режима дозирования? Пульмонология. 2023; 33 (1): 44–50. DOI:10.18093/0869-0189-2023-33-1-44-50.; Tashkin D.P., Celli B., Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359 (15): 1543–1554. DOI:10.1056/NEJMoa0805800.; Rodrigo G.J., Castro-Rodriguez J.A., Nannini L.J. et al. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir. Med. 2009; 103 (10): 1421–1429. DOI:10.1016/j.rmed.2009.05.020.; Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat inhaler and the risk of death in COPD. N. Engl. J. Med. 2013; 369 (16): 1491–1501. DOI:10.1056/NEJMoa1303342.; Halpin D.M., Dahl R., Hallmann C. et al. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10: 239–259. DOI:10.2147/COPD.S75146.; Anzueto A., Wise R., Calverley P. et al. The Tiotropium safety and performance in Respimat® (TIOSPIR®) trial: spirometry outcomes. Respir. Res. 2015; 16 (1): 107. DOI:10.1186/s12931-015-0269-4.; Capstick T.G., Clifton I.J. Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma. Expert Rev. Respir. Med. 2012; 6 (1): 91–101. DOI:10.1586/ers.11.89.; Государственный реестр лекарственных средств. Сведения о лекарственном средстве Респиум®. Доступно на: https://grls.rosminzdrav.ru/grls.aspx?s=%D0%9B%D0%9F-006263&m=RegistrationCertificateNumberTest; The COPD Assessment Test (CAT). Available at: https://www.catestonline.orgTest/; Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC. Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). Br. Med. J. 1960; 2 (5213): 1665. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2098438/?page=1Test; https://journal.pulmonology.ru/pulm/article/view/4394Test
الإتاحة: https://doi.org/10.18093/0869-0189-2023-33-6-810-818Test
https://doi.org/10.1016/S2213-2600Test(21)00511-7
https://doi.org/10.1016/S0140-6736Test(21)01169-7
https://doi.org/10.1164/rccm.201207-1299OCTest
https://doi.org/10.18093/0869-0189-2023-33-5-587-594Test
https://doi.org/10.1056/NEJMoa1008378Test
https://doi.org/10.1016/S2213-2600Test(13)70158-9
https://doi.org/10.1592/phco.23.2.183.32082Test
https://doi.org/10.1136/thorax.55.4.289Test
https://doi.org/10.1164/ajrccm.161.4.9903044Test -
2دورية أكاديمية
المصدر: PULMONOLOGIYA; Том 31, № 5 (2021); 645-652 ; Пульмонология; Том 31, № 5 (2021); 645-652 ; 2541-9617 ; 0869-0189
مصطلحات موضوعية: единый ингалятор, long-acting β2-agonist, long-acting muscarinic antagonist, all-cause mortality, exacerbations, hospitalizations, triple therapy, single-inhaler triple therapy, обострения, госпитализации, ингаляционные глюкокортикостероиды, длительно действующие β2-агонисты, длительно действующие антихолинергические препараты, трехкомпонентная терапия
وصف الملف: application/pdf
العلاقة: https://journal.pulmonology.ru/pulm/article/view/2884/2288Test; World Health Organization (WHO). Health statistics and information systems: projections of mortality and causes of death, 2016 to 2060. 2016. Available at: https://www.who.int/healthinfo/global_burden_disease/projections/enTest/ [Accessed: February 11, 2021].; Fletcher M.J., Upton J., Taylor-Fishwick J. et al. COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health. 2011; 11: 612. DOI:10.1186/1471-2458-11-612.; Global Initiative for Chronic Obstructive Lung Disease (COLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2021 Report. Available at: https://goldcopd.org/2021-gold-reportsTest/ [Accessed: May 11, 2021].; Guarascio A.J., Ray S.M., Finch C.K., Self T.H. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon. Outcomes Res. 2013; 5: 235–245.https://doi.org/10.2147/CEOR.S34321Test.; Miller J.D., Foster T., Boulanger L. et al. Direct costs of COPD in the U.S.: an analysis of Medical Expenditure Panel Survey (MEPS) data. COPD. 2005; 2 (3): 311–318. DOI:10.1080/15412550500218221.; Miravitlles M., Murio C., Guerrero T., Gisbert R. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002; 121 (5): 1449–1455. DOI:10.1378/chest.121.5.1449.; Strassels S.A., Smith D.H., Sullivan S.D., Mahajan P.S. The costs of treating COPD in the United States. Chest. 2001; 119 (2): 344–352. DOI:10.1378/chest.119.2.344.; Rehman A.U., Ahmad Hassali M.A., Muhammad S.A. et al. The economic burden of chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature. Expert Rev. Pharmacoecon. Outcomes Res. 2020: 20 (6): 661–672. DOI:10.1080/14737167.2020.1678385.; Chenna P.R., Mannino D.M. Outcomes of severe COPD exacerbations requiring hospitalization. Semin. Respir. Crit. Care Med. 2010; 31 (3): 286–294.https://doi.org/10.1055/s-0030-1254069Test.; Halpin D.M., Decramer M., Celli B. et al. Exacerbation frequency and course of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2012; 7: 653–661. DOI:10.2147/COPD.S34186.; Halpin D.M., Miravitlles M., Metzdorf N., Celli B. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int. J. Chron. Obstruct Pulmon. Dis. 2017; 12: 2891–2908. DOI:10.2147/COPD.S139470.; Fitch K., Iwasaki K., Pyenson B. et al. Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis. Curr. Med. Res. Opin. 2011; 27 (7): 1425–1429. DOI:10.1185/03007995.2011.583230.; Ferguson G.T., Rabe K.F., Martinez F.J. et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018; 6 (10): 747–758. DOI:10.1016/S2213-2600(18)30327-8.; Lipson D.A., Barnacle H., Birk R. et al. FULEIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am. J. Respir Crit. Care Med. 2017; 196 (4): 438–446. DOI:10.1164/rccm.201703-0449OC.; Lipson D.A., Barnhart F., Brealey N. et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 2018; 378 (18): 1671–1680. DOI:10.1056/NEJMoa1713901.; Papi A., Vestbo J., Fabbri L. et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018; 391 (10125): 1076–1084. DOI:10.1016/S0140-6736(18)30206-X.; Rabe K.F., Martinez F.J., Ferguson G.T. et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N. Engl. J. Med. 2020; 383 (1): 35–48. DOI:10.1056/NEJMoa1916046.; Singh D., Papi A., Corradi M. et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016; 388 (10048): 963–973. DOI:10.1016/S0140-6736(16)31354-X.; Vestbo J., Fabbri L., Papi A. et al. Inhaled corticosteroid containing combinations and mortality in COPD. Eur. Respir. J. 2018; 52 (6): 1801230. DOI:10.1183/13993003.01230-2018.; Agusti A., Fabbri L.M., Singh D. et al. Inhaled corticosteroids in COPD: friend or foe? Eur. Respir. J. 2018; 52 (6): 1801219. DOI:10.1183/13993003.01219-2018.; Lipworth B., Kuo C.R., Jabbal S. Current appraisal of single inhaler triple therapy in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 3003–3009. DOI:10.2147/COPD.S177333.; Vanfleteren L., Fabbri L.M., Papi A. et al. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 3971–3981. DOI:10.2147/COPD.S185975.; Mammen M.J., Lloyd D.R., Kumar S. et al. Triple therapy versus dual or monotherapy with long-acting bronchodilators for chronic obstructive pulmonary disease. A systematic review and meta-analysis. Ann. Am. Thorac. Soc. 2020; 17 (10): 1308–1318. DOI:10.1513/AnnalsATS.202001-023OC.; Hartley B.F., Barnes N.C., Lettis S. et al. Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis. Respir. Res. 2020; 21 (1): 5. DOI:10.1186/s12931-019-1262-0.; European Medicines Agency (EMA). Pharmacovigilance Risk Assessment Committee (PRAC), recommendation 2016. Inhaled corticosteroids (ICS) containing medicinal products indicated in the treatment of chronic obstructive pulmonary disease (COPD). Available at: https://www.ema.europa.eu/en/medicines/human/referrals/inhaled-corticosteroids-containing-medicinal-products-indicated-treatment-chronic-obstructiveTest [Accessed: February 11, 2021].; European Medicines Agency (EMA). Committee for Medicinal Products for Human Use (CHMP). International non-proprietary name: beclometasone dipropionate/formoterol fumarate dehydrate/glycopyrronium. Assessment report 2018. Procedure No.EMEA/H/C/004257/II/0002. Available at: https://www.ema.europa.eu/en/documents/variation-report/trimbow-h-c-4257-ii-0002-epar-assessmentreport-variation_en.pdfTest [Accessed: February 11, 2021].; Han M.K., Criner G.J., Dransfield M.T. et al. The effect of inhaled corticosteroid withdrawal and baseline inhaled treatment on exacerbations in the IMPACT study. A randomized, double-blind, multicenter clinical trial. Am. J. Respir. Crit. Care Med. 2020; 202 (9): 1237–1243. DOI:10.1164/rccm.201912-2478OC.; EU Clinical Trials Register. A multinational, multicentre, randomised, open-label, active-controlled, 26-week, 2-arm, parallel group study to evaluate the non-inferiority of fixed combination of beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide administered via pMDI (CHF 5993) versus fixed combination of fluticasone furoate plus vilanterol administered via DPI (Relvar®) plus tiotropium bromide (Spiriva®) for the treatment of patients with chronic obstructive pulmonary disease. EudraCT No.2014-001487-35. Available at: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001487-35/LTTest [Accessed: February 11, 2021].; Gershon A.S., Guan J., Victor J.C. et al. Quantifying health services use for chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2013; 187 (6): 596-601. DOI:10.1164/rccm.201211-2044OC.; Johannesdottir S.A., Christiansen C.F., Johansen M.B. et al. Hospitalization with acute exacerbation of chronic obstructive pulmonary disease and associated health resource utilization: a population-based Danish cohort study. J. Med. Econ. 2013; 16 (7): 897–906. DOI:10.3111/13696998.2013.800525.; Soler-Cataluna J. J, Martinez-Garcia M.A., Roman S. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60 (11): 925–931. DOI:10.1136/thx.2005.040527.; Soler-Cataluna J.J., Martinez-Garcia M.A., Sanchez L.S. et al. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir. Med. 2009; 103 (5): 692–699. DOI:10.1016/j.rmed.2008.12.005.; Rothnie K.J., Mullerova H., Smeeth L., Quint J.K. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2018; 198 (4): 464–471. DOI:10.1164/rccm.201710-2029OC.; Lipson D.A., Crim C., Criner G.J. et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am. J. Respir.Crit. Care Med. 2020; 201 (12): 1508-1516. DOI:10.1164/rccm.201911-2207OC.; Anthonisen N.R., Skeans M.A., Wise R.A. et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142 (4): 233–239. DOI:10.7326/0003-4819-142-4-200502150-00005.; Yusuf S., Sleight P., Pogue J. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 2000; 342 (3): 145–153. DOI:10.1056/NEJM200001203420301.; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360 (9326): 7–22. DOI:10.1016/S0140-6736(02)09327-3.; Calverley P.M.A., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J Med. 2007; 356 (8): 775–789. DOI:10.1056/NEJMoa063070.; Vestbo J., Anderson J.A., Brook R.D. et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016; 387 (10030): 1817–1826. DOI:10.1016/S0140-6736(16)30069-1.; Williams N.P., Coombs N.A., Johnson M.J. et al. Seasonality, risk factors and burden of community-acquired pneumonia in COPD patients: a population database study using linked health care records. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 313–322. DOI:10.2147/COPD.S121389.; Vestbo J., Papi A., Corradi M. et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017; 389 (10082): 1919–1929. DOI:10.1016/S0140-6736(17)30188-5.; Dransfield M.T., Bourbeau J., Jones P.W. et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013; 1 (3): 210–223. DOI:10.1016/S2213-2600(13)70074-2.; Williams N.P., Ostridge K., Devaster J.M. et al. Impact of radiologically stratified exacerbations: insights into pneumonia aetiology in COPD. Respir. Res. 2018; 19 (1): 143. DOI:10.1186/s12931-018-0842-8.; Saleh A., Lopez-Campos J.L., Hartl S. et al. The effect of incidental consolidation on management and outcomes in COPD exacerbations: data from the European COPD audit. PLoS One. 2015; 10 (7): e0134004. DOI:10.1371/journal.pone.0134004.; Dransfield M.T., Crim C., Criner G.J. et al. Risk of exacerbation and pneumonia with single-inhaler triple versus dual therapy in IMPACT. Ann. Am. Thorac. Soc. 2021; 18 (5): 788–798. DOI:10.1513/AnnalsATS.202002-096OC.; Pascoe S., Barnes N., Brusselle G. et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir. Med. 2019; 7 (9): 745–756. DOI:10.1016/S2213-2600(19)30190-0.; Bafadhel M., Peterson S., De Blas M.A. et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir. Med. 2018; 6 (2): 117–126. DOI:10.1016/S2213-2600(18)30006-7.; Pascoe S., Pavord I., Hinds D. et al. The association between blood eosinophils and risk and treatment outcome in COPD is not dichotomised. Lancet Respir. Med. 2018; 6 (5): e18. DOI:10.1016/S2213-2600(18)30137-1.; Halpin D.M.G., Worsley S., Ismaila A.S. et al. Intrepid: clinical effectiveness of once-daily single-inhaler fluticasone furoate/umeclidinium/ vilanterol versus multiple-inhaler triple therapy in usual clinical practice. Am. J. Respir. Crit. Care Med. 2020; 201: A4313. DOI:10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A4313.; https://journal.pulmonology.ru/pulm/article/view/2884Test
الإتاحة: https://doi.org/10.18093/0869-0189-2021-31-5-645-652Test
https://doi.org/10.1186/1471-2458-11-612Test
https://doi.org/10.2147/CEOR.S34321Test
https://doi.org/10.1080/15412550500218221Test
https://doi.org/10.1378/chest.121.5.1449Test
https://doi.org/10.1378/chest.119.2.344Test
https://doi.org/10.1080/14737167.2020.1678385Test
https://doi.org/10.1055/s-0030-1254069Test
https://doi.org/10.2147/COPD.S34186Test
https://doi.org/10.2147/COPD.S139470Test
